CD38 antigen receptor membrane‐modified MSC‐derived extracellular vesicle (CD38‐ARM‐MSC‐EV) associated technology is a promising agent with high clinical potential against pulmonary fibrosis.[233]. Here, CD38 is linked to pulmonary fibrosis.